Cyclosporine Market Size, Share, & Industry Analysis Report By Indication (Transplant rejection prophylaxis, Rheumatoid arthritis), By Dosage Form, By Route of Administration, By Distribution Channel, and By Region

Description

List of Tables

The cyclosporine market size is expected to reach USD 7.06 Billion by 2034, according to a new study by Polaris Market Research. The report "Cyclosporine Market Share, Size, Trends, Industry Analysis Report: By Indication (Transplant rejection prophylaxis, Rheumatoid arthritis, Psoriasis), By Dosage Form, By Route of Administration, By Distribution Channel, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Cyclosporine is an immunosuppressive agent widely used to prevent organ transplant rejection and manage autoimmune conditions, where precise immune modulation is crucial for treatment success. Developed under stringent clinical protocols, it ensures controlled immune response and consistent therapeutic outcomes. The market continues to grow as healthcare systems expand access to advanced immunosuppressive therapies for systemic and ophthalmic applications.

The market growth is fueled by rising government healthcare spending and the increasing number of organ transplantation procedures globally. The rising advancement in drug formulations and delivery systems are enhancing patient compliance and therapeutic efficiency. Additionally, the expanding prevalence of autoimmune disorders and chronic ocular inflammation is driving the broader clinical adoption of cyclosporine across multiple specialties.

Cyclosporine Market Report Highlights

Based on indication, the transplant rejection prophylaxis segment dominated the market in 2024, due to the rising number of kidney, liver, and heart transplant surgeries requiring long-term immunosuppressive therapy.

Based on dosage form, the eye drops segment is expected to witness the fastest growth, driven by increasing diagnoses of dry eye disease and chronic ocular surface inflammation.

Based on route of administration, the oral segment held the dominant market share in 2024, driven by its use in systemic autoimmune conditions and widespread availability across hospital and retail channels.

Based on distribution channel, the hospital pharmacies segment held the dominant share in 2024, due to the centralized management of post-transplant medication regimens and the high demand for physician-supervised dispensing of immunosuppressants.

North America accounted for largest share of the global cyclosporine market in 2024, fueled by strong healthcare spending and robust adoption of generic immunosuppressive therapies.

Asia Pacific is expected to grow fastest during the forecast period, due to increasing access to organ transplantation and growing prevalence of autoimmune diseases.

A few global key market players include AbbVie Inc., AdvaCare Pharma, Apotex Inc., Cipla Ltd., Harrow, Inc., Lupin Pharmaceuticals, Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, and Viatris Inc.

Polaris Market Research has segmented the market report on the basis of indication, dosage form, route of administration, distribution channel, and region:

By Indication Outlook (Revenue, USD Billion, 2020-2034)

Transplant rejection prophylaxis

Rheumatoid arthritis

Psoriasis

Autoimmune myasthenia gravis

Dry eye

Other indications

By Dosage Form Outlook (Revenue, USD Billion, 2020-2034)

Capsule

Eye drops

Liquid solutions

Creams and ointments

By Route of Administration (Revenue, USD Billion, 2020-2034)

Oral

Intravenous

Topical

By Distribution Channel (Revenue, USD Billion, 2020-2034)

Hospital pharmacies

Retail pharmacies

Online pharmacies

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin Americ

Product Code: PM6000

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Cyclosporine Market Insights

4.1. Cyclosporine Market - Market Snapshot
4.2. Cyclosporine Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing Government Healthcare Spending
  - 4.2.1.2. Rising Cases of Organ Transplant Procedures Worldwide
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Availability of Alternatives
  - 4.2.2.2. Competition from Alternative Recreational Options
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Cyclosporine Market Trends
4.6. Value Chain Analysis

5. Global Cyclosporine Market, by Indication Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
5.3. Transplant rejection prophylaxis
- 5.3.1. Global Cyclosporine Market, by Transplant rejection prophylaxis, by Region, 2020-2034 (USD Billion)
5.4. Rheumatoid arthritis
- 5.4.1. Global Cyclosporine Market, by Rheumatoid arthritis, by Region, 2020-2034 (USD Billion)
5.5. Psoriasis
- 5.5.1. Global Cyclosporine Market, by Psoriasis, by Region, 2020-2034 (USD Billion)
5.6. Autoimmune myasthenia gravis
- 5.6.1. Global Cyclosporine Market, by Autoimmune myasthenia gravis, by Region, 2020-2034 (USD Billion)
5.7. Dry eye
- 5.7.1. Global Cyclosporine Market, by Dry eye, by Region, 2020-2034 (USD Billion)
5.8. Other indications
- 5.8.1. Global Cyclosporine Market, by Other indications, by Region, 2020-2034 (USD Billion)

6. Global Cyclosporine Market, by Dosage Form

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
6.3. Capsule
- 6.3.1. Global Cyclosporine Market, by Capsule, by Region, 2020-2034 (USD Billion)
6.4. Eye drops
- 6.4.1. Global Cyclosporine Market, by Eye drops, by Region, 2020-2034 (USD Billion)
6.5. Liquid solutions
- 6.5.1. Global Cyclosporine Market, by Liquid solutions, by Region, 2020-2034 (USD Billion)
6.6. Creams and ointments
- 6.6.1. Global Cyclosporine Market, by Creams and ointments, by Region, 2020-2034 (USD Billion)

7. Global Cyclosporine Market, by Route of Administration

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
7.3. Oral
- 7.3.1. Global Cyclosporine Market, by Oral, by Region, 2020-2034 (USD Billion)
7.4. Intravenous
- 7.4.1. Global Cyclosporine Market, by Intravenous, by Region, 2020-2034 (USD Billion)
7.5. Topical
- 7.5.1. Global Cyclosporine Market, by Topical, by Region, 2020-2034 (USD Billion)

8. Global Cyclosporine Market, by Distribution Channel

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
8.3. Hospital pharmacies
- 8.3.1. Global Cyclosporine Market, by Hospital pharmacies, by Region, 2020-2034 (USD Billion)
8.4. Retail pharmacies
- 8.4.1. Global Cyclosporine Market, by Retail pharmacies, by Region, 2020-2034 (USD Billion)
8.5. Online pharmacies
- 8.5.1. Global Cyclosporine Market, by Online pharmacies, by Region, 2020-2034 (USD Billion)

9. Global Cyclosporine Market, by Geography

9.1. Key Findings
9.2. Introduction
- 9.2.1. Cyclosporine Market Assessment, By Geography, 2020-2034 (USD Billion)
9.3. Cyclosporine Market - North America
- 9.3.1. North America: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.3.2. North America: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.3.3. North America: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.3.4. North America: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.5. Cyclosporine Market - U.S.
  - 9.3.5.1. U.S.: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.3.5.2. U.S.: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.3.5.3. U.S.: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.3.5.4. U.S.: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.6. Cyclosporine Market - Canada
  - 9.3.6.1. Canada: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.3.6.2. Canada: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.3.6.3. Canada: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.3.6.4. Canada: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
9.4. Cyclosporine Market - Europe
- 9.4.1. Europe: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.4.2. Europe: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.3. Europe: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.4.4. Europe: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.5. Cyclosporine Market - UK
  - 9.4.5.1. UK: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.5.2. UK: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.5.3. UK: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.5.4. UK: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.6. Cyclosporine Market - France
  - 9.4.6.1. France: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.6.2. France: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.6.3. France: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.6.4. France: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.7. Cyclosporine Market - Germany
  - 9.4.7.1. Germany: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.7.2. Germany: Cyclosporine Market, by Dosage Form ,2020-2034 (USD Billion)
  - 9.4.7.3. Germany: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.7.4. Germany: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.8. Cyclosporine Market - Italy
  - 9.4.8.1. Italy: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.8.2. Italy: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.8.3. Italy: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.8.4. Italy: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.9. Cyclosporine Market - Spain
  - 9.4.9.1. Spain: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.9.2. Spain: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.9.3. Spain: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.9.4. Spain: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.10. Cyclosporine Market - Netherlands
  - 9.4.10.1. Netherlands: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.10.2. Netherlands: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.10.3. Netherlands: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.10.4. Netherlands: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.11. Cyclosporine Market - Russia
  - 9.4.11.1. Russia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.11.2. Russia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.11.3. Russia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.11.4. Russia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.12. Cyclosporine Market - Rest of Europe
  - 9.4.12.1. Rest of Europe: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.4.12.2. Rest of Europe: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.4.12.3. Rest of Europe: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.4.12.4. Rest of Europe: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
9.5. Cyclosporine Market - Asia Pacific
- 9.5.1. Asia Pacific: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.5. Cyclosporine Market - China
  - 9.5.5.1. China: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.5.2. China: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.5.3. China: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.5.4. China: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.6. Cyclosporine Market - India
  - 9.5.6.1. India: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.6.2. India: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.6.3. India: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.6.4. India: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.7. Cyclosporine Market - Malaysia
  - 9.5.7.1. Malaysia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.7.2. Malaysia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.7.3. Malaysia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.7.4. Malaysia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.8. Cyclosporine Market - Japan
  - 9.5.8.1. Japan: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.8.2. Japan: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.8.3. Japan: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.8.4. Japan: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.9. Cyclosporine Market - Indonesia
  - 9.5.9.1. Indonesia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.9.2. Indonesia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.9.3. Indonesia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.9.4. Indonesia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.10. Cyclosporine Market - South Korea
  - 9.5.10.1. South Korea: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.10.2. South Korea: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.10.3. South Korea: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.10.4. South Korea: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.11. Cyclosporine Market - Australia
  - 9.5.11.1. Australia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.11.2. Australia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.11.3. Australia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.11.4. Australia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.12. Cyclosporine Market - Rest of Asia Pacific
  - 9.5.12.1. Rest of Asia Pacific: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.5.12.2. Rest of Asia Pacific: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.5.12.3. Rest of Asia Pacific: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.5.12.4. Rest of Asia Pacific: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
9.6. Cyclosporine Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.5. Cyclosporine Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.6.5.2. Saudi Arabia: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.6.5.3. Saudi Arabia: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.6.5.4. Saudi Arabia: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.6. Cyclosporine Market - UAE
  - 9.6.6.1. UAE: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.6.6.2. UAE: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.6.6.3. UAE: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.6.6.4. UAE: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.7. Cyclosporine Market - Israel
  - 9.6.7.1. Israel: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.6.7.2. Israel: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.6.7.3. Israel: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.6.7.4. Israel: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.8. Cyclosporine Market - South Africa
  - 9.6.8.1. South Africa: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.6.8.2. South Africa: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.6.8.3. South Africa: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.6.8.4. South Africa: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.9. Cyclosporine Market - Rest of Middle East & Africa
  - 9.6.9.1. Rest of Middle East & Africa: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.6.9.2. Rest of Middle East & Africa: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.6.9.3. Rest of Middle East & Africa: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.6.9.4. Rest of Middle East & Africa: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
9.7. Cyclosporine Market - Latin America
- 9.7.1. Latin America: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.5. Cyclosporine Market - Mexico
  - 9.7.5.1. Mexico: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.7.5.2. Mexico: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.7.5.3. Mexico: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.7.5.4. Mexico: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.6. Cyclosporine Market - Brazil
  - 9.7.6.1. Brazil: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.7.6.2. Brazil: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.7.6.3. Brazil: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.7.6.4. Brazil: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.7. Cyclosporine Market - Argentina
  - 9.7.7.1. Argentina: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.7.7.2. Argentina: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.7.7.3. Argentina: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.7.7.4. Argentina: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.8. Cyclosporine Market - Rest of Latin America
  - 9.7.8.1. Rest of Latin America: Cyclosporine Market, by Indication Type, 2020-2034 (USD Billion)
  - 9.7.8.2. Rest of Latin America: Cyclosporine Market, by Dosage Form, 2020-2034 (USD Billion)
  - 9.7.8.3. Rest of Latin America: Cyclosporine Market, by Route of Administration, 2020-2034 (USD Billion)
  - 9.7.8.4. Rest of Latin America: Cyclosporine Market, by Distribution Channel, 2020-2034 (USD Billion)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. AbbVie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. AdvaCare Pharma
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Apotex Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Cipla Ltd.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Harrow, Inc.
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Lupin Pharmaceuticals, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Novartis AG
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Santen Pharmaceutical Co., Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Strides Pharma Science Ltd.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Sun Pharmaceutical Industries Ltd.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
11.11. Teva Pharmaceutical Industries
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
11.12. Viatris Inc.
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development